npj Breast Cancer

Article	Citations
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer	351
Triple negative breast cancer: Pitfalls and progress	184
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now	146
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group	126
Immunotherapy in breast cancer: an overview of current strategies and perspectives	117
Evolution of HER2-low expression from primary to recurrent breast cancer	113
Connected-UNets: a deep learning architecture for breast mass segmentation	78
Large language model (ChatGPT) as a support tool for breast tumor board	77
Immunotherapy for early triple negative breast cancer: research agenda for the next decade	77
Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer	64
PARP inhibition in breast cancer: progress made and future hopes	62
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment	58
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer	55
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy	50
The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment	47
Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma	45
Circulating tRNA-derived small RNAs (tsRNAs) signature for the diagnosis and prognosis of breast cancer	44
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer	42
Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis	41
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL	40
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors	40
An emerging generation of endocrine therapies in breast cancer: a clinical perspective	40
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer	39
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer	38
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies	38

Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort	37
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer	35
Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer	35
Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge	35
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups	34
IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer	33
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis	33
Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation	32
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study	32
A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes	32
Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis	31
A careful reassessment of anthracycline use in curable breast cancer	30
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer	30
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk	30
Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression	29
Potential of ultra-high-resolution photon-counting CT of bone metastases: initial experiences in breast cancer patients	29
Deep learning models for histologic grading of breast cancer and association with disease prognosis	27
The clinical and molecular significance associated with STING signaling in breast cancer	27
Allostatic load: a framework to understand breast cancer outcomes in Black women	26
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer	26
Oncogene-mediated metabolic gene signature predicts breast cancer outcome	26
MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis	26
Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway	25
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer	25
The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data	25
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer	24
Integrative multiomics-histopathology analysis for breast cancer classification	24
Subclonal heterogeneity and evolution in breast cancer	23
A randomized intervention involving family to improve communication in breast cancer care	23
How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies	22
Effects of systemic inflammation on relapse in early breast cancer	22
Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients	21
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer	21
Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations	21
MicroRNA-200c restoration reveals a cytokine profile to enhance M1 macrophage polarization in breast cancer	21
Comprehensive characterization of distinct genetic alterations in metastatic breast cancer across various metastatic sites	21
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study	21
FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity	21
Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants	21
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer	21
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer	20
Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome	20
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)	20
HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer	20
De-escalation in breast cancer surgery	20
Concomitant analyses of intratumoral microbiota and genomic features reveal distinct racial differences in breast cancer	20
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy	19
Long non-coding RNA MIR200CHG promotes breast cancer proliferation, invasion, and drug resistance by interacting with and stabilizing YB-1	19
Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer	19
Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality	19

High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes	19
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE	19
Automated percent mammographic density, mammographic texture variation, and risk of breast cancer: a nested case-control study	19
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness	18
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study	18
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases	18
Predicting breast cancer types on and beyond molecular level in a multi-modal fashion	18
The human intermediate prolactin receptor is a mammary proto-oncogene	18
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer	18
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan	18
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence	18
Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours	18
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients	18
Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies	18
Circulating cell-free DNA-based methylation patterns for breast cancer diagnosis	17
Circulating amino acids and amino acid-related metabolites and risk of breast cancer among predominantly premenopausal women	17
Crown-like structures in breast adipose tissue of breast cancer patients: associations with CD68 expression, obesity, metabolic factors and prognosis	17
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial	17
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer	17
Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6	17
Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America	16
Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer	16
Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma	16
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing	16
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease	16
Unmasking the immune microecology of ductal carcinoma in situ with deep learning	16
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy	16
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036	15
Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer	15
Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer	15
Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation	15
Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance	15
Immune landscape of breast tumors with low and intermediate estrogen receptor expression	15
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®	15
RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis	15
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis	14
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy	14
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer	14
Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB	14
Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer	14
Sensory nerves enhance triple-negative breast cancer invasion and metastasis via the axon guidance molecule PlexinB3	14
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer	14
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab	14
The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis	14
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer	14
Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ	14
Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib	13
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer	13
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer	13
Clinical outcomes of de novo metastatic HER2-low breast cancer: a National Cancer Database Analysis	13
High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia	13
Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery	13
Ancestry-associated transcriptomic profiles of breast cancer in patients of African, Arab, and European ancestry	13
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells	13
Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer	13
The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ	13
Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy	13
Acupuncture versus cognitive behavioral therapy for pain among cancer survivors with insomnia: an exploratory analysis of a randomized clinical trial	13
Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology	13
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer	13
Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid	12
Risk of primary lung cancer after adjuvant radiotherapy in breast cancer—a large population-based study	12
Breast cancer dormancy is associated with a 4NG1 state and not senescence	12
Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature	12
Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial	12
Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?	12
Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer	12
Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer	12
Endoplasmic reticulum stress inhibits AR expression via the PERK/eIF2α/ATF4 pathway in luminal androgen receptor triple-negative breast cancer and prostate cancer	12
Association between the nucleosome footprint of plasma DNA and neoadjuvant chemotherapy response for breast cancer	12
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013	12
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer	12
Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers	12
Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer	12
Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score	12
Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer	12
The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment	11
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer	11
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer	11
Co-dependency for MET and FGFR1 in basal triple-negative breast cancers	11

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR	11
Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy	11
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial	11
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings	11
Anti-tumor effects of an ID antagonist with no observed acquired resistance	11
Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing	11
Adolescent alcohol, nuts, and fiber: combined effects on benign breast disease risk in young women	11
Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer	11
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer	11
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors	11
Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study	11
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer	11
Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials	10
Stem-like breast cancer cells in the activated state resist genetic stress via TGFBI-ZEB1	10
Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination	10
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance	10
STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer	10
High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer	10
Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief	10
Inherited predisposition to breast cancer in the Carolina Breast Cancer Study	10
Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells	10
The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study	10
Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication	10
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models	10
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy	10
High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing	10
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition	10
Do current family history-based genetic testing guidelines contribute to breast cancer health inequities?	9
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled	9
Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy	9
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response	9
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer	9
Mechanostimulation of breast myoepithelial cells induces functional changes associated with DCIS progression to invasion	9
Deep learning model improves tumor-infiltrating lymphocyte evaluation and therapeutic response prediction in breast cancer	9
Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts	9
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer	9
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer	9
Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer	9
A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis	9
Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer	9
Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study	9
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers	9
Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers	8
Is conservative management of ductal carcinoma in situ risky?	8
Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects	8
Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection	8
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial	8
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer	8
Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates	8
Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy	8
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients	8
Evaluation of overall survival and barriers to surgery for patients with breast cancer treated without surgery: a National Cancer Database analysis	8
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)	8
Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer	8
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer	8
Adaptive stress response genes associated with breast cancer subtypes and survival outcomes reveal race-related differences	8
S-nitrosylated and non-nitrosylated COX2 have differential expression and distinct subcellular localization in normal and breast cancer tissue	8
Mobile mammography in New York City: analysis of 32,350 women utilizing a screening mammogram program	8
Rare subtypes of triple negative breast cancer: Current understanding and future directions	8
LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer	7
Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer	7
Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy	7
Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations	7
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial	7
Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses	7
The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer	7
SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2	7
Establishment and characterization of immortalized human breast cancer cell lines from breast cancer patient-derived xenografts (PDX)	7
Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies	7
UACA locus is associated with breast cancer chemoresistance and survival	7
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients	7
TGFβ-mediated MMP13 secretion drives myoepithelial cell dependent breast cancer progression	7
Predicting neoadjuvant chemotherapy benefit using deep learning from stromal histology in breast cancer	7
Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development	7
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit	7
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models	7
Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning	7
Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ	7
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer	6
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study	6
Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients	6
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer	6
The cytosolic iron–sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors	6
Automated and rapid detection of cancer in suspicious axillary lymph nodes in patients with breast cancer	6
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study	6
Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression	6
Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapy	6
A common goal to CARE: Cancer Advocates, Researchers, and Clinicians Explore current treatments and clinical trials for breast cancer brain metastases	6
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer	6
The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer	6
Mortality after second malignancy in breast cancer survivors compared to a first primary cancer: a nationwide longitudinal cohort study	6
Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial	6
Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer	6
Unravelling the clinicopathological and functional significance of replication protein A (RPA) heterotrimeric complex in breast cancers	6
GnRHa protects the ovarian reserve by reducing endoplasmic reticulum stress during cyclophosphamide-based chemotherapy	6